243 related articles for article (PubMed ID: 11602851)
1. Prevention of bone loss and fracture after lung transplantation: a pilot study.
Cahill BC; O'Rourke MK; Parker S; Stringham JC; Karwande SV; Knecht TP
Transplantation; 2001 Oct; 72(7):1251-5. PubMed ID: 11602851
[TBL] [Abstract][Full Text] [Related]
2. Intravenous bisphosphonate prevents symptomatic osteoporotic vertebral collapse in patients after liver transplantation.
Reeves HL; Francis RM; Manas DM; Hudson M; Day CP
Liver Transpl Surg; 1998 Sep; 4(5):404-9. PubMed ID: 9724478
[TBL] [Abstract][Full Text] [Related]
3. Bone mineral density in lung-transplant recipients before and after graft: prevention of lumbar spine post-transplantation-accelerated bone loss by pamidronate.
Trombetti A; Gerbase MW; Spiliopoulos A; Slosman DO; Nicod LP; Rizzoli R
J Heart Lung Transplant; 2000 Aug; 19(8):736-43. PubMed ID: 10967266
[TBL] [Abstract][Full Text] [Related]
4. Prevention of bone loss after heart transplantation with antiresorptive therapy: a pilot study.
Shane E; Rodino MA; McMahon DJ; Addesso V; Staron RB; Seibel MJ; Mancini D; Michler RE; Lo SH
J Heart Lung Transplant; 1998 Nov; 17(11):1089-96. PubMed ID: 9855448
[TBL] [Abstract][Full Text] [Related]
5. Better late than never? Experience with intravenous pamidronate treatment in patients with low bone mass or fractures following cardiac or liver transplantation.
Dodidou P; Bruckner T; Hosch S; Haass M; Klar E; Sauer P; Ziegler R; Leidig-Bruckner G
Osteoporos Int; 2003 Jan; 14(1):82-9. PubMed ID: 12577189
[TBL] [Abstract][Full Text] [Related]
6. Bone density in heart or lung transplant recipients--a longitudinal study.
Wang TK; O'Sullivan S; Gamble GD; Ruygrok PN
Transplant Proc; 2013; 45(6):2357-65. PubMed ID: 23747143
[TBL] [Abstract][Full Text] [Related]
7. Osteoporosis in lung transplantation candidates with end-stage pulmonary disease.
Shane E; Silverberg SJ; Donovan D; Papadopoulos A; Staron RB; Addesso V; Jorgesen B; McGregor C; Schulman L
Am J Med; 1996 Sep; 101(3):262-9. PubMed ID: 8873487
[TBL] [Abstract][Full Text] [Related]
8. Intravenous pamidronate as treatment for osteoporosis after heart transplantation: a prospective study.
Krieg MA; Seydoux C; Sandini L; Goy JJ; Berguer DG; Thiébaud D; Burckhardt P
Osteoporos Int; 2001; 12(2):112-6. PubMed ID: 11303710
[TBL] [Abstract][Full Text] [Related]
9. Changes in bone mineral density after kidney transplantation: 2-year assessment of a French cohort.
Segaud N; Legroux I; Hazzan M; Noel C; Cortet B
Osteoporos Int; 2018 May; 29(5):1165-1175. PubMed ID: 29500526
[TBL] [Abstract][Full Text] [Related]
10. Bone densitometry should be included in the evaluation of candidates for lung transplantation.
Dodd VA; Staron RB; Papadopoulos A; Evans L; Schulman LL; Jorgensen B; Gerow-Smith R; Shane E
J Transpl Coord; 1999 Jun; 9(2):119-23. PubMed ID: 10703394
[TBL] [Abstract][Full Text] [Related]
11. Comparison of alendronate and pamidronate on bone loss in kidney transplant patients for the first 6 months of transplantation.
Omidvar B; Ghorbani A; Shahbazian H; Beladi Mousavi SS; Shariat Nabavi SJ; Alasti M
Iran J Kidney Dis; 2011 Nov; 5(6):420-4. PubMed ID: 22057076
[TBL] [Abstract][Full Text] [Related]
12. Prevention of osteoporosis in heart transplant recipients: a comparison of calcitriol with calcitonin and pamidronate.
Bianda T; Linka A; Junga G; Brunner H; Steinert H; Kiowski W; Schmid C
Calcif Tissue Int; 2000 Aug; 67(2):116-21. PubMed ID: 10920215
[TBL] [Abstract][Full Text] [Related]
13. The effect of intravenous pamidronate versus oral alendronate on bone mineral density in patients with osteoporosis.
Vis M; Bultink IE; Dijkmans BA; Lems WF
Osteoporos Int; 2005 Nov; 16(11):1432-5. PubMed ID: 15883662
[TBL] [Abstract][Full Text] [Related]
14. Aging bone and osteoporosis: strategies for preventing fractures in the elderly.
Ettinger MP
Arch Intern Med; 2003 Oct; 163(18):2237-46. PubMed ID: 14557222
[TBL] [Abstract][Full Text] [Related]
15. Patient satisfaction and efficacy of switching from weekly bisphosphonates to monthly minodronate for treatment and prevention of glucocorticoid-induced osteoporosis in Japanese patients with systemic rheumatic diseases: a randomized, clinical trial.
Tamechika SY; Sasaki K; Hayami Y; Ohmura SI; Maeda S; Iwagaitsu S; Naniwa T
Arch Osteoporos; 2018 Jun; 13(1):67. PubMed ID: 29904824
[TBL] [Abstract][Full Text] [Related]
16. Bone loss and fracture after lung transplantation.
Shane E; Papadopoulos A; Staron RB; Addesso V; Donovan D; McGregor C; Schulman LL
Transplantation; 1999 Jul; 68(2):220-7. PubMed ID: 10440391
[TBL] [Abstract][Full Text] [Related]
17. Response to alendronate in osteoporotic women previously treated with pamidronate.
Peretz A; Siderova V; Body JJ; Dumon JC; Rozenberg S; Fellemans C; Fuss M; Bergmann P;
Maturitas; 2003 Feb; 44(2):111-5. PubMed ID: 12590006
[TBL] [Abstract][Full Text] [Related]
18. Bisphosphonates for osteoporosis in people with cystic fibrosis.
Brenckmann C; Papaioannou A
Cochrane Database Syst Rev; 2001; (4):CD002010. PubMed ID: 11687132
[TBL] [Abstract][Full Text] [Related]
19. Prevention of bone loss and vertebral fractures in patients with chronic epilepsy--antiepileptic drug and osteoporosis prevention trial.
Lazzari AA; Dussault PM; Thakore-James M; Gagnon D; Baker E; Davis SA; Houranieh AM
Epilepsia; 2013 Nov; 54(11):1997-2004. PubMed ID: 24010637
[TBL] [Abstract][Full Text] [Related]
20. Determinants of change in bone mineral density and fracture risk during bisphosphonate holiday.
Xu LH; Adams-Huet B; Poindexter JR; Maalouf NM
Osteoporos Int; 2016 May; 27(5):1701-8. PubMed ID: 26642963
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
